Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-03-30
Based on 1112 first isolates · ED · Cystitis (lower UTI) · 2024-03-31 → 2025-03-30
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (82 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
86 %
n = 85
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
82 %
n = 85
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
84 %
n = 85
ciprofloxacin CIP
trend · Escherichia coli
80 %
76 %
n = 85
mecillinam MEC
trend · Escherichia coli lower UTI only
79 %
79 %
n = 85
ceftriaxone CRO
trend · Escherichia coli
79 %
76 %
n = 85
trimethoprim TMP
trend · Escherichia coli lower UTI only
75 %
74 %
n = 85
74 %
74 %
n = 85
52 %
59 %
n = 85
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
12 %
n = 85
5 %
6 %
n = 85
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
1 %
n = 85

Most likely organisms for this profile

Escherichia coli
55 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.